The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …

Tapping into the innate immune system's power, nanovaccines can induce tumor-specific
immune responses, which is a promising strategy in cancer immunotherapy. However …

New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA)
family, and has been identified as one of the most immunogenic tumor-associated antigens …

Chimeric antigen receptor T cells (CAR-T) therapy has shown great potential in tumor
treatment. However, many factors impair the efficacy of CAR-T therapy, such as antigenic …

Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in
adults. As supplements to standard of care (SOC), various immunotherapies improve the …

The high prevalence and rising incidence of autoimmune diseases have become a
prominent public health issue. Autoimmune disorders result from the immune system …

Abstract Claudin18. 2 (CLDN18. 2) is highly expressed with the development of various
malignant tumors, especially gastrointestinal cancers, and is emerging as a new target for …

Advancing personalized medicine in brain cancer relies on innovative strategies, with
mRNA vaccines emerging as a promising avenue. While the initial use of mRNA vaccines …